Literature DB >> 24679494

Pathophysiology of portal hypertension.

Yasuko Iwakiri1.   

Abstract

Portal hypertension is a major complication of liver disease that results from a variety of pathologic conditions that increase the resistance to the portal blood flow into the liver. As portal hypertension develops, the formation of collateral vessels and arterial vasodilation progresses, which results in increased blood flow to the portal circulation. Hyperdynamic circulatory syndrome develops, leading to esophageal varices or ascites. This article summarizes the factors that increase (1) intrahepatic vascular resistance and (2) the blood flow in the splanchnic and systemic circulations in liver cirrhosis. In addition, the future directions of basic/clinical research in portal hypertension are discussed.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Fibrosis; Hyperdynamic circulation; Lymphatic system; Nitric oxide; Splenomegaly

Mesh:

Year:  2014        PMID: 24679494      PMCID: PMC3971388          DOI: 10.1016/j.cld.2013.12.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  83 in total

Review 1.  The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  J Clin Gastroenterol       Date:  2007 Nov-Dec       Impact factor: 3.062

2.  Impaired extracellular matrix degradation in aortic vessels of cirrhotic rats.

Authors:  Guillermo Fernández-Varo; Manuel Morales-Ruiz; Josefa Ros; Sònia Tugues; Javier Muñoz-Luque; Gregori Casals; Vicente Arroyo; Juan Rodés; Wladimiro Jiménez
Journal:  J Hepatol       Date:  2006-11-13       Impact factor: 25.083

3.  Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability.

Authors:  Jorge Gracia-Sancho; Bàrbara Laviña; Aina Rodríguez-Vilarrupla; Héctor García-Calderó; Mercedes Fernández; Jaume Bosch; Joan-Carles García-Pagán
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

4.  Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers.

Authors:  Jorge Gracia-Sancho; Bàrbara Laviña; Aina Rodríguez-Vilarrupla; Héctor García-Calderó; Jaime Bosch; Joan Carles García-Pagán
Journal:  J Hepatol       Date:  2007-04-05       Impact factor: 25.083

5.  Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.

Authors:  William Kemp; Henry Krum; John Colman; Michael Bailey; Tim Yandle; Mark Richards; Stuart Roberts
Journal:  Liver Int       Date:  2007-11       Impact factor: 5.828

Review 6.  Vascular endothelial dysfunction in cirrhosis.

Authors:  Yasuko Iwakiri; Roberto J Groszmann
Journal:  J Hepatol       Date:  2007-03-05       Impact factor: 25.083

7.  Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.

Authors:  Mercedes Fernandez; Marc Mejias; Ester Garcia-Pras; Raul Mendez; Juan Carlos Garcia-Pagan; Jaime Bosch
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

Review 8.  Vascular deterioration in cirrhosis: the big picture.

Authors:  Jaime Bosch
Journal:  J Clin Gastroenterol       Date:  2007 Nov-Dec       Impact factor: 3.062

9.  Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.

Authors:  Jonel Trebicka; Ludger Leifeld; Martin Hennenberg; Erwin Biecker; Andreas Eckhardt; Nicolas Fischer; Andrea Schulze Pröbsting; Christoph Clemens; Frank Lammert; Tilman Sauerbruch; Jörg Heller
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

10.  Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells.

Authors:  Erica Novo; Stefania Cannito; Elena Zamara; Lorenzo Valfrè di Bonzo; Alessandra Caligiuri; Carlo Cravanzola; Alessandra Compagnone; Sebastiano Colombatto; Fabio Marra; Massimo Pinzani; Maurizio Parola
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

View more
  56 in total

1.  Brain-Derived Neurotrophic Factor and Supraoptic Vasopressin Neurons in Hyponatremia.

Authors:  Kirthikaa Balapattabi; Joel T Little; Martha Bachelor; J Thomas Cunningham
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 4.914

Review 2.  Portal hypertension induced by congenital hepatic arterioportal fistula: report of four clinical cases and review of the literature.

Authors:  Dan-Ying Zhang; Shu-Qiang Weng; Ling Dong; Xi-Zhong Shen; Xu-Dong Qu
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

3.  Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.

Authors:  Jianrong Wang; Wenxia Lu; Jingjing Li; Rong Zhang; Yuqing Zhou; Qin Yin; Yuanyuan Zheng; Fan Wang; Yujing Xia; Kan Chen; Sainan Li; Tong Liu; Jie Lu; Yingqun Zhou; Chuan-Yong Guo
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

Review 4.  Pathophysiology and Management of Variceal Bleeding.

Authors:  Saleh A Alqahtani; Sunguk Jang
Journal:  Drugs       Date:  2021-03-12       Impact factor: 9.546

5.  Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Jin Woo Choi; Jin Wook Chung; Dong Ho Lee; Hyo-Cheol Kim; Saebeom Hur; Myungsu Lee; Hwan Jun Jae
Journal:  Eur Radiol       Date:  2017-12-07       Impact factor: 5.315

Review 6.  The portal hypertension syndrome: etiology, classification, relevance, and animal models.

Authors:  Jaime Bosch; Yasuko Iwakiri
Journal:  Hepatol Int       Date:  2017-10-24       Impact factor: 6.047

Review 7.  Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis.

Authors:  Antonio Facciorusso; Annabianca Amoruso; Viviana Neve; Matteo Antonino; Valentina Del Prete; Michele Barone
Journal:  World J Hepatol       Date:  2014-11-27

8.  Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms.

Authors:  Mary C Drinane; Usman Yaqoob; Haibin Yu; Fanghong Luo; Thomas Greuter; Juan P Arab; Enis Kostallari; Vikas K Verma; Jessica Maiers; Thiago Milech De Assuncao; Michael Simons; Debabrata Mukhopadhyay; Tatiana Kisseleva; David A Brenner; Raul Urrutia; Gwen Lomberk; Yandong Gao; Giovanni Ligresti; Daniel J Tschumperlin; Alexander Revzin; Sheng Cao; Vijay H Shah
Journal:  JCI Insight       Date:  2017-12-21

9.  Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data.

Authors:  Morgan E Grams; Yingying Sang; Josef Coresh; Shoshana Ballew; Kunihiro Matsushita; Miklos Z Molnar; Zoltan Szabo; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

Review 10.  Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment.

Authors:  Mariia Zadorozhna; Sante Di Gioia; Massimo Conese; Domenica Mangieri
Journal:  Mol Biol Rep       Date:  2020-02-10       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.